<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Haderk F</submitter><journal>Nature communications</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11068778</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer</pubmed_title><pmcid>PMC11068778</pmcid><pubmed_authors>Cech L</pubmed_authors><pubmed_authors>Barbosa Rabago D</pubmed_authors><pubmed_authors>Haderk F</pubmed_authors><pubmed_authors>Goodarzi H</pubmed_authors><pubmed_authors>Roth J</pubmed_authors><pubmed_authors>Allegakoen D</pubmed_authors><pubmed_authors>Gomez C</pubmed_authors><pubmed_authors>Riess J</pubmed_authors><pubmed_authors>Yu J</pubmed_authors><pubmed_authors>Shah K</pubmed_authors><pubmed_authors>Meraz I</pubmed_authors><pubmed_authors>Roose J</pubmed_authors><pubmed_authors>Fernandez-Mendez C</pubmed_authors><pubmed_authors>Tang T</pubmed_authors><pubmed_authors>Wu W</pubmed_authors><pubmed_authors>Huang B</pubmed_authors><pubmed_authors>Kerr D</pubmed_authors><pubmed_authors>Tamaki W</pubmed_authors><pubmed_authors>Santisteban P</pubmed_authors><pubmed_authors>Nanjo S</pubmed_authors><pubmed_authors>Kuo C</pubmed_authors><pubmed_authors>Bivona T</pubmed_authors><pubmed_authors>Guan J</pubmed_authors><pubmed_authors>Olivas V</pubmed_authors><pubmed_authors>Chou Y</pubmed_authors><pubmed_authors>Pourmoghadam Y</pubmed_authors><pubmed_authors>Majidi M</pubmed_authors><pubmed_authors>Gutkind J</pubmed_authors><pubmed_authors>Rotow J</pubmed_authors><pubmed_authors>Herrington K</pubmed_authors><pubmed_authors>Gbenedio O</pubmed_authors><pubmed_authors>Post L</pubmed_authors><pubmed_authors>Bandyopadhyay S</pubmed_authors><pubmed_authors>Blakely C</pubmed_authors><pubmed_authors>McCoach C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer</name><description/><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2026-06-02T02:11:30.349Z</modification><creation>2026-04-13T03:13:02.108Z</creation></dates><accession>S-EPMC11068778</accession><cross_references/></HashMap>